Study of JNJ-90189892 for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, JNJ-90189892, for people with certain types of blood cancers (acute myeloid leukemia or higher-risk myelodysplastic neoplasms) that have come back or not responded to treatment. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with acute myeloid leukemia or a high-risk form of myelodysplastic neoplasms (MDS) that has returned or not improved after treatment, OR you must have untreated acute myeloid leukemia.
- Your weight must be at least 40 kg (about 88 lbs).
- You should be able to take care of yourself and be up and about (ECOG score 0 to 2).
- Your kidneys must work well enough, as measured by a test (eGFR of 40 or higher).
- You cannot need extra oxygen or have serious lung problems.
- You must not have active infections, allergies to the study drug, or cancer that has spread to the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This Phase 1/2 study tests enzomenib (DSP-5336) in people with relapsed or hard-to-treat acute leukemia (and, in some places, certain other blood cancers). The goal is to see how the drug works and how safe it is, especially for leukemia cases with specific genetic changes (KMT2A/MLL or NPM1).
This trial tests a new drug called JNJ-95804306 for people with certain blood cancers (like acute myeloid leukemia, myelodysplastic syndromes, or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The goal is to see if the drug is safe and if it can help.
This study tests whether adding a new medicine called IPN60340 to two standard leukemia treatments (azacitidine and venetoclax) works better than those two treatments alone. It's for people newly diagnosed with acute myeloid leukemia who cannot tolerate aggressive chemotherapy due to age or other health conditions.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.